➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
Colorcon
McKinsey
Johnson and Johnson

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,592,211

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,592,211
Title:Compositions for improvement of brain function
Abstract: A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.
Inventor(s): Pierzynowski; Stefan (Trelleborg, SE)
Assignee:
Application Number:14/428,841
Patent Claims:1. A method of promoting nerve growth, comprising administering a composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and a lipase, a protease and an amylase to a subject in need thereof.

2. The method of treatment according to claim 1, wherein the treatment comprises administering an amount of the composition containing 0.1-30 g AKG to a patient per day.

3. The method of treatment according to claim 1, wherein the composition comprises 3000-300000 USP units of Burkholderia cepacia lipase per g AKG, 2000-200000 USP units of Aspergillus melleus protease per g AKG, and 300-30000 USP units of Aspergillus oryzae amylase per g AKG.

4. The method of treatment according to claim 1, wherein the lipase is selected from the group consisting of a mammalian lipase, a microbial lipase, a bacterial lipase, a pancrelipase lipase, a liprotamase lipase, a Pseudomonas lipase, a human or other mammalian bile-salt stimulated lipase (BSSL), a human or other mammalian bile-salt dependent lipase (BSDL), a Rhizopus oryzae lipase, a Chromobacterium viscosum lipase, a Rhizopus delemar lipase, a Burkholderia lipase, a Burkholderia cepacia lipase, and a Burkholderia cepacia lipase as cross-linked lipase crystals.

5. The method of treatment according to claim 1, wherein the protease is selected from the group consisting of a mammalian protease, a microbial protease, a fungal protease, a pancrelipase protease, a liprotamase protease, an Aspergillus protease and an Aspergillus melleus protease.

6. The method of treatment according to claim 1, wherein the amylase is selected from the group consisting of a mammalian amylase, a microbial amylase, a fungal amylase, a pancrelipase amylase, a liprotamase amylase, an Aspergillus amylase and Aspergillus oryzae amylase.

7. The method of claim 1, wherein the number of nerve cells is increased.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1200567Sep 19, 2012
PCT Information
PCT FiledSeptember 19, 2013PCT Application Number:PCT/SE2013/051098
PCT Publication Date:March 27, 2014PCT Publication Number:WO2014/046603

Details for Patent 9,592,211

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725 001 2009-04-30   Start Trial 2032-09-19 RX search
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725 002 2009-04-30   Start Trial 2032-09-19 RX search
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725 003 2009-04-30   Start Trial 2032-09-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
McKinsey
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.